News
Article
Author(s):
Whole genome sequencing market is projected to grow significantly, driven by advancements in technology and personalized medicine, reaching $6.1 billion by 2030.
A BCC Research study predicts the global whole genome market to double its net worth from 2025 by the year 2030.
Stock.adobe.com
BCC Research revealed results from its most recent study “Whole Genome Sequencing: Global Markets,” showing expectations for growth from $3 billion in 2025 to $6.1 billion in 2030. This estimation was calculated using a compound annual growth rate (CAGR) of 15.1% beginning in 2025 up until the target year of 2020.
The report provided by BCC Research provides insight into both the current and future market potential of whole genome sequencing (WGS). The report provides projections on global and regional markets through 2030 including market estimates by product and service, covering instruments, consumables, and other various services.
Workflow is segmented into three sections, pre-sequencing, sequencing, and data analysis. The targeted end users for this study are research institutes, hospitals & clinics, pharmaceutical organizations, and other smaller entities. Application of WGS is aimed for treatment of infectious diseases, cancer research, rare genetic diseases, and pharmacogenomics, with the report dividing the data into four regions:
The importance of these results stem from WGS emerging as a powerful tool used to diagnose, treat, and monitor various conditions such as cancer, rare inherited disorders, and neurological diseases. WGS’ ability to provide clear and concise genomic data assists in decreasing reliance on single-gene tests, along with invasive procedures as treatment options. WGS is also seeing an expanded role in drug development cycles identifying improved disease targets, along with being used on acceptable patients during clinical studies.
The BCC Research study provided the following factors leading to the expected growth over the next five years.
BCC Research’s study also yielded results show a shift in focus to expand personal genomics and prenatal testing increasing market growth across all four designated regions. Results also provided data supporting WGS-based diagnostics leading to an increase in precise diagnoses for patients while simultaneously giving patients more personalized treatment solutions.
Additional findings showed North America as the highest market share region accounting for 50.9% of market share in 2024. The report goes on to list consumables as the expected dominant product type through 20230.
BCC Research provides market research reports designed to be objective, unbiased in measurement, and provides an assessment of market opportunities. BCC Research aims to deliver informed business decisions without distractions to maintain its objective and unbiased viewpoint.
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
